Phenotypic Susceptibility Data Associated With the Most Common INI Resistance Mutation Patterns Present in 192 Virus Isolates From 105 Patients
| Primary Mutations* | No. of Unique Viruses† | Published In vitro Susceptibility Data§ | |||
| Without accessory mutations | With accessory mutations | Raltegravir | Elvitegravir | S/GSK1349572 | |
| 148H + 140S | 26 | 18 | >150 [2, 9, 11, 21–23] | >150 [2, 9, 11, 22–23] | 3 [11] |
| 148R + 140S | 5 | 0 | >150 [9, 11, 21, 23] | >150 [9, 23] | 8 [11] |
| 148R + 140A | 2 | 1 | >150 [21, 23] | >150 [23] | NA |
| 148R | 5 | 0 | 10 to 50 [8–9, 11, 21] | 90 to 150 [8–9, 11] | 1 [11] |
| 148K | 1 | 0 | 25 to 40 [2, 9–11, 21] | 80 [2, 9–11] | 1 [11] |
| Totals | 39 | 19 | |||
| 155H | 11 | 24 | 10 to 30 [8–11, 21–22] | 20 to 50 [2, 8–11, 22] | 1 [11] |
| 155H + 92Q | 1 | 2 | 80 to 150 [11, 21] | 125 to 150 [2, 11] | 3 [11] |
| Totals | 12 | 26 | |||
| 143R | 7 | 1 | 15 to 20 [11, 21] | 2 [11] | 1 [11] |
| 143R + 97A | 2 | 7 | >150 [21] | NA | NA |
| 143C + 97A | 2 | 4 | >150 [18, 21] | NA | NA |
| 143C | 0 | 2 | 3 to 4 [11, 21] | 1.5 [11] | 1 [11] |
| Totals | 11 | 14 | |||
| Primary Mutations* | No. of Unique Viruses† | Published In vitro Susceptibility Data§ | |||
| Without accessory mutations | With accessory mutations | Raltegravir | Elvitegravir | S/GSK1349572 | |
| 148H + 140S | 26 | 18 | >150 [2, 9, 11, 21–23] | >150 [2, 9, 11, 22–23] | 3 [11] |
| 148R + 140S | 5 | 0 | >150 [9, 11, 21, 23] | >150 [9, 23] | 8 [11] |
| 148R + 140A | 2 | 1 | >150 [21, 23] | >150 [23] | NA |
| 148R | 5 | 0 | 10 to 50 [8–9, 11, 21] | 90 to 150 [8–9, 11] | 1 [11] |
| 148K | 1 | 0 | 25 to 40 [2, 9–11, 21] | 80 [2, 9–11] | 1 [11] |
| Totals | 39 | 19 | |||
| 155H | 11 | 24 | 10 to 30 [8–11, 21–22] | 20 to 50 [2, 8–11, 22] | 1 [11] |
| 155H + 92Q | 1 | 2 | 80 to 150 [11, 21] | 125 to 150 [2, 11] | 3 [11] |
| Totals | 12 | 26 | |||
| 143R | 7 | 1 | 15 to 20 [11, 21] | 2 [11] | 1 [11] |
| 143R + 97A | 2 | 7 | >150 [21] | NA | NA |
| 143C + 97A | 2 | 4 | >150 [18, 21] | NA | NA |
| 143C | 0 | 2 | 3 to 4 [11, 21] | 1.5 [11] | 1 [11] |
| Totals | 11 | 14 | |||
NOTE. The viral sequences in this table were obtained from 12 published references in the Stanford HIV Drug Resistance Database [32].
*G140SA and T97A are in this column because of their strong association with Q148 and Y143 mutations, respectively. Accessory mutations include the mutations in the second half of Table 1 (except G140SA and T97A). Viruses with primary mutations belonging to more than one pathway are not shown. †The totals of these 2 columns consist of 121 viruses containing one of the 3 most common raltegravir-associated mutational patterns. §In vitro susceptibility data obtained using the PhenoSense assay, the Antivirogram, or one of the generic HeLa-CD4+ reporter gene assay variants. Viruses containing G140 + Q148 mutations may have up 10- to 20-fold decreased S/GSK1349572 susceptibility when a third INI resistance mutation is present [11, 33].
Phenotypic Susceptibility Data Associated With the Most Common INI Resistance Mutation Patterns Present in 192 Virus Isolates From 105 Patients
| Primary Mutations* | No. of Unique Viruses† | Published In vitro Susceptibility Data§ | |||
| Without accessory mutations | With accessory mutations | Raltegravir | Elvitegravir | S/GSK1349572 | |
| 148H + 140S | 26 | 18 | >150 [2, 9, 11, 21–23] | >150 [2, 9, 11, 22–23] | 3 [11] |
| 148R + 140S | 5 | 0 | >150 [9, 11, 21, 23] | >150 [9, 23] | 8 [11] |
| 148R + 140A | 2 | 1 | >150 [21, 23] | >150 [23] | NA |
| 148R | 5 | 0 | 10 to 50 [8–9, 11, 21] | 90 to 150 [8–9, 11] | 1 [11] |
| 148K | 1 | 0 | 25 to 40 [2, 9–11, 21] | 80 [2, 9–11] | 1 [11] |
| Totals | 39 | 19 | |||
| 155H | 11 | 24 | 10 to 30 [8–11, 21–22] | 20 to 50 [2, 8–11, 22] | 1 [11] |
| 155H + 92Q | 1 | 2 | 80 to 150 [11, 21] | 125 to 150 [2, 11] | 3 [11] |
| Totals | 12 | 26 | |||
| 143R | 7 | 1 | 15 to 20 [11, 21] | 2 [11] | 1 [11] |
| 143R + 97A | 2 | 7 | >150 [21] | NA | NA |
| 143C + 97A | 2 | 4 | >150 [18, 21] | NA | NA |
| 143C | 0 | 2 | 3 to 4 [11, 21] | 1.5 [11] | 1 [11] |
| Totals | 11 | 14 | |||
| Primary Mutations* | No. of Unique Viruses† | Published In vitro Susceptibility Data§ | |||
| Without accessory mutations | With accessory mutations | Raltegravir | Elvitegravir | S/GSK1349572 | |
| 148H + 140S | 26 | 18 | >150 [2, 9, 11, 21–23] | >150 [2, 9, 11, 22–23] | 3 [11] |
| 148R + 140S | 5 | 0 | >150 [9, 11, 21, 23] | >150 [9, 23] | 8 [11] |
| 148R + 140A | 2 | 1 | >150 [21, 23] | >150 [23] | NA |
| 148R | 5 | 0 | 10 to 50 [8–9, 11, 21] | 90 to 150 [8–9, 11] | 1 [11] |
| 148K | 1 | 0 | 25 to 40 [2, 9–11, 21] | 80 [2, 9–11] | 1 [11] |
| Totals | 39 | 19 | |||
| 155H | 11 | 24 | 10 to 30 [8–11, 21–22] | 20 to 50 [2, 8–11, 22] | 1 [11] |
| 155H + 92Q | 1 | 2 | 80 to 150 [11, 21] | 125 to 150 [2, 11] | 3 [11] |
| Totals | 12 | 26 | |||
| 143R | 7 | 1 | 15 to 20 [11, 21] | 2 [11] | 1 [11] |
| 143R + 97A | 2 | 7 | >150 [21] | NA | NA |
| 143C + 97A | 2 | 4 | >150 [18, 21] | NA | NA |
| 143C | 0 | 2 | 3 to 4 [11, 21] | 1.5 [11] | 1 [11] |
| Totals | 11 | 14 | |||
NOTE. The viral sequences in this table were obtained from 12 published references in the Stanford HIV Drug Resistance Database [32].
*G140SA and T97A are in this column because of their strong association with Q148 and Y143 mutations, respectively. Accessory mutations include the mutations in the second half of Table 1 (except G140SA and T97A). Viruses with primary mutations belonging to more than one pathway are not shown. †The totals of these 2 columns consist of 121 viruses containing one of the 3 most common raltegravir-associated mutational patterns. §In vitro susceptibility data obtained using the PhenoSense assay, the Antivirogram, or one of the generic HeLa-CD4+ reporter gene assay variants. Viruses containing G140 + Q148 mutations may have up 10- to 20-fold decreased S/GSK1349572 susceptibility when a third INI resistance mutation is present [11, 33].
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
